Search Results 771-780 of 16375 for monoclonal antibody

1. A Study to Evaluate Effectiveness and Safety of Lenzilumab in Hospitalized Patients with COVID-19 Pneumonia (Enrolling by Invitation Only) - Mayo Clinic

   ... monoclonal antibody or kinase inhibitor. Participation in clinical trials ... Use of any neutralizing monoclonal antibodies such as bamlanivimab (LY ...

2. Brain Tumor Clinical Trials - Mayo Clinic Research

   Monoclonal antibodies, such as ... Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan.

3. Sarcoma Clinical Trials

   Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find ...

4. Testing the Addition of an Anti-cancer Drug, ASTX727, to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer - Mayo Clinic

   Patients who have received prior PD-1/PD-L1 monoclonal antibodies in any disease setting are eligible. ... antibody agent, ASTX727 is a hypomethylating ...

5. Safety Study of SEA-CD40 in Cancer Patients - Mayo Clinic

   Other monoclonal antibodies, antibody-drug conjugates, or radioimmunoconjugates: 4 weeks (2 weeks with documented disease progression);; T-cell or other cell ...

6. A Study of the Use of Pembrolizumab (MK-3475) in Patients with Relapsed or Hard to Treat Classical Hodgkin Lymphoma - Mayo Clinic

   Prior monoclonal antibody within 4 weeks prior to study Day 1; Prior Chemotherapy, targeted small molecular therapy, or radiation therapy within 2 weeks ...

7. Publications - David Dingli, M.D., Ph.D. - Mayo Clinic

   Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. Leukemia 2022 Mar; 36 (3):873-876 ...

8. A Study to Assess the Effectiveness, Safety, and Drug/Body Interactions of Rovalpituzumab for Third-Line and Later Treatment of Patients with Small Cell Lung Cancer that has Returned or is Resistant to Treatment - Mayo Clinic

   ... monoclonal antibodies): 2 weeks; Immune-checkpoint inhibitors (i.e., anti-PD-1, anti-PD-L1, or anti-CTLA-4): 4 weeks; Other monoclonal antibodies, antibody ...

9. VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer - Mayo Clinic

   A history of hypersensitivity to other humanized monoclonal antibodies. Significant cardiovascular disease (New York Heart Association Class II or greater) ...

10. Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer - Mayo Clinic

    Monoclonal antibodies;; Anti-HER2 or other "targeted" (e.g., mTOR) therapy. *Note: Any adverse events derived from these therapies must be ≤ Grade 2 prior ...